Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies.

Autor: Mohty R; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Dulery R; Department of Hematology, Saint Antoine Hospital, AP-HP, Paris, France.; Sorbonne University, INSERM UMRs 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France., Bazarbachi AH; Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA., Savani M; Division of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, AZ, USA., Hamed RA; Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA., Bazarbachi A; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Mohty M; Department of Hematology, Saint Antoine Hospital, AP-HP, Paris, France. mohamad.mohty@inserm.fr.; Sorbonne University, INSERM UMRs 938, Centre de Recherche Saint-Antoine (CRSA), Paris, France. mohamad.mohty@inserm.fr.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2021 Jul 09; Vol. 11 (7), pp. 126. Date of Electronic Publication: 2021 Jul 09.
DOI: 10.1038/s41408-021-00518-z
Abstrakt: Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody-drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: